Table 3.

Genotype frequencies of selected polymorphisms in selenoproteins and association with prostate cancer risk in the EPIC-Heidelberg nested case-control study

Gene SNP (rsNo.)GenotypeCases (%)Controls (%)HWE*OR95% CI
SEP15GG165 (66.5)309 (62.8)1.00
G1125AGA78 (31.5)157 (31.9)0.84(0.60, 1.17)
(rs5859)AA5 (2.0)26 (5.3)
0.31
SEP15CC165 (66.5)325 (66.1)1.00
C>TCT78 (31.5)142 (28.9)0.98(0.70, 1.37)
(rs540049)TT5 (2.0)25 (5.1)
0.07
SEPP1GG152 (61.3)271 (55.1)1.00
G>A codingGA86 (34.7)194 (39.4)0.80(0.58, 1.10)
Ala234ThrAA10 (4.0)27 (5.5)0.66(0.31, 1.39)
(rs3877899)0.31
SEPP1GG116 (46.8)250 (50.8)1.00
G>A 3′UTRGA105 (42.3)209 (42.5)1.08(0.78, 1.49)
(rs7579)AA27 (10.9)33 (6.7)1.72(0.99, 2.98)
0.22
GPX1CC123 (49.8)264 (54.2)1.00
C>TCT108 (43.7)181 (37.2)1.30(0.95, 1.78)
Pro198LeuTT16 (6.5)42 (8.6)0.81(0.44, 1.49)
(rs1050450)0.18
GPX4CC77 (31.4)156 (31.8)1.00
C718TCT114 (46.5)229 (46.7)1.00(0.70, 1.44)
(rs713041)TT54 (22.0)105 (21.4)1.03(0.68, 1.57)
0.22
  • *P value of χ2 test for deviation from HWE in controls.

  • Conditional logistic regression stratified by matching factors (age group and time of blood collection).